Schmitz S A, Wagner S, Schuhmann-Giampieri G, Krause W, Wolf K J
Department of Radiology, Benjamin Franklin University Hospital Steglitz, Free University Berlin, Germany.
Radiology. 1997 Feb;202(2):407-12. doi: 10.1148/radiology.202.2.9015066.
The suitability of the hepatobiliary contrast medium gadoxetic acid disodium, or Gd-EOB-DTPA, for liver enhancement at computed tomography (CT) was studied.
CT attenuation levels at 120 kV were measured in samples of increasing concentrations of gadolinium (gadoxetic acid disodium) or iodine (iopromide) in aqueous solutions in vitro. In dogs, CT attenuation in the liver was measured up to 90 minutes after a single intravenous injection of 0.3, 0.5, and 0.7 mmol Gd/kg gadoxetic acid disodium (three dogs per dose group). In addition, three VX2 tumor-bearing rabbits were examined (0.7 mmol Gd/kg).
In vitro, the CT attenuation of gadolinium is 40% higher than that of iodine if calculated per milligram of gadolinium and iodine, respectively. In dogs, the median net increase in liver enhancement was 25, 33, and 43 HU with a dose of 0.3, 0.5, and 0.7 mmol Gd/kg, respectively. The gallbladder and bile ducts became clearly visible. In rabbits, liver enhancement of 25 HU provided improved visualization of the unenhanced tumor.
Because of the higher CT attenuation of gadolinium compared with iodine and because of its liver-specific uptake, gadoxetic acid disodium is a contrast medium that may improve diagnosis of pathologic liver conditions at CT.
研究肝胆造影剂钆塞酸二钠（Gd-EOB-DTPA）在计算机断层扫描（CT）中用于肝脏增强的适用性。
体外测量不同浓度钆（钆塞酸二钠）或碘（碘普罗胺）水溶液样本在120 kV时的CT衰减水平。在犬类中，单次静脉注射0.3、0.5和0.7 mmol钆/千克钆塞酸二钠后90分钟内测量肝脏的CT衰减（每个剂量组三只犬）。此外，对三只VX2荷瘤兔进行了检查（0.7 mmol钆/千克）。
体外实验中，按每毫克钆和碘分别计算，钆的CT衰减比碘高40%。在犬类中，剂量为0.3、0.5和0.7 mmol钆/千克时，肝脏增强的净增加中位数分别为25、33和43 HU。胆囊和胆管清晰可见。在兔类中，25 HU的肝脏增强改善了未增强肿瘤的可视化效果。
由于钆的CT衰减高于碘，且具有肝脏特异性摄取，钆塞酸二钠是一种可改善CT对肝脏病理状况诊断的造影剂。
